184 related articles for article (PubMed ID: 22356470)
1. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Coleman C; Hubble J; Schwab J; Beffy JL; Picaut P; Morte C
Int J Neurosci; 2012 Jul; 122(7):358-62. PubMed ID: 22356470
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.
Charles D; Brashear A; Hauser RA; Li HI; Boo LM; Brin MF;
Clin Neuropharmacol; 2012; 35(5):208-14. PubMed ID: 22948497
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
6. Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport
Simonetta-Moreau M; Picaut P; Volteau M; Poewe W
Eur J Neurol; 2019 Jun; 26(6):943-e65. PubMed ID: 30168896
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
[TBL] [Abstract][Full Text] [Related]
9. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
10. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.
Lew MF; Brashear A; Dashtipour K; Isaacson S; Hauser RA; Maisonobe P; Snyder D; Ondo W
Int J Neurosci; 2018 Jul; 128(7):619-626. PubMed ID: 29343142
[TBL] [Abstract][Full Text] [Related]
11. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
Trosch RM; Espay AJ; Truong D; Gil R; Singer C; LeWitt PA; Lew MF; Tagliati M; Adler CH; Chen JJ; Marchese D; Comella CL
J Neurol Sci; 2017 May; 376():84-90. PubMed ID: 28431634
[TBL] [Abstract][Full Text] [Related]
12. A 17-year experience of abobotulinumtoxina in cervical dystonia.
Vivancos-Matellano F; Ybot-Gorrin I; Diez-Tejedor E
Int J Neurosci; 2012 Jul; 122(7):354-7. PubMed ID: 22329596
[TBL] [Abstract][Full Text] [Related]
13. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
[TBL] [Abstract][Full Text] [Related]
14. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
16. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
18. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W;
Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831
[TBL] [Abstract][Full Text] [Related]
19. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
Hauser RA; Truong D; Hubble J; Coleman C; Beffy JL; Chang S; Picaut P
J Neural Transm (Vienna); 2013 Feb; 120(2):299-307. PubMed ID: 22878514
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
